← Back to Search

Macrolide Antibiotic

Clarithromycin for Multiple Myeloma (BiRd vs Rd Trial)

Phase 3

Waitlist Available

Led By Adriana Rossi, MD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 5 years

Awards & highlights

BiRd vs Rd Trial Summary

This trial will compare the effectiveness of two different treatments for multiple myeloma. One treatment is a combination of three drugs, and the other is just two drugs.

Eligible Conditions

Multiple Myeloma

BiRd vs Rd Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Survival Duration Without Disease Progression

Secondary outcome measures

Functional Assessment of Chronic Illness Therapy - Fatigue Subscale (FS; Version 4) Score of Patients Receiving BiRd vs Rd Treatment

Number of Adverse Events Experienced

Number of Days After Initiating Treatment With BiRd Regimen to Disease Progression, as Compared to Subjects on Rd Treatment Regimen.

+7 more

Side effects data

From 2021 Phase 3 trial • 1046 Patients • NCT04167670

Diarrhoea

Dysgeusia

100%

80%

60%

40%

20%

Study treatment Arm

Vonoprazan Dual Therapy

Vonoprazan Triple Therapy

Lansoprazole Triple Therapy

BiRd vs Rd Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: BiRD treatment regimenExperimental Treatment3 Interventions

Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.

Group II: Rd treatment regimenActive Control2 Interventions

Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lenalidomide

2005

Completed Phase 3

~1480

Clarithromycin

2017

Completed Phase 4

~3950

Dexamethasone

2007

Completed Phase 4

~2590

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Celgene CorporationIndustry Sponsor

444 Previous Clinical Trials

58,224 Total Patients Enrolled

73 Trials studying Multiple Myeloma

10,537 Patients Enrolled for Multiple Myeloma

Weill Medical College of Cornell UniversityLead Sponsor

1,055 Previous Clinical Trials

1,316,283 Total Patients Enrolled

18 Trials studying Multiple Myeloma

759 Patients Enrolled for Multiple Myeloma

Adriana Rossi, MDPrincipal InvestigatorWeill Medical College of Cornell University

1 Previous Clinical Trials

36 Total Patients Enrolled

1 Trials studying Multiple Myeloma

36 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the Clarithromycin drug's standing with the FDA?

"Clarithromycin has received a 3 for safety. This is because it is a Phase 3 drug, which means that not only has it shown some efficacy in trials, but also that there is a significant amount of data supporting its safety."

Answered by AI

How many research subjects are enrolling in this clinical trial?

"Unfortunately, this study is not currently looking for patients. However, there are 751 other clinical trials for Clarithromycin and 826 for multiple myeloma that are currently open for enrolment."

Answered by AI

What is the medical research history of Clarithromycin?

"The first study conducted on clarithromycin was in 2002 at the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. As of now, there are 1517 completed studies and 751 actively recruiting trials. Most of these active studies are taking place in Aurora, Colorado."

Answered by AI

What is Clarithromycin most often given to patients for?

"Clarithromycin is a medication used to treat ophthalmia, sympathetic. It can also be used to manage at least two prior systemic chemotherapy regimens, branch retinal vein occlusion, and macular edema."

Answered by AI

Are people still being accepted into this research project?

"As of now, this study is not looking for any more patients. This particular clinical trial was originally posted on February 1st, 2016 and was last updated on February 1st, 2022. If you're interested in other studies, 826 are actively recruiting patients with multiple myeloma and 751 are recruiting participants for Clarithromycin."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

2016. "BiRd vs. Rd as Initial Therapy in Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02516696.